Ultragenyx is trading at $14.37, up 11.57%, as biotechnology rebounds and XBI rises 2.55%.
- The rebound reflects a stronger industry outlook and renewed M&A optimism.
- No new company-specific announcement on September 17, 2026 clearly explains the move; the September 2 Angelman syndrome Phase 3 failure remains the latest major company news, after the trial missed its primary and key secondary endpoints.
- Broader risk appetite is likely supporting today’s recovery.